NCT04080271

Brief Summary

The aim of this study is to detect bone metastases by PET/CT examination in cancer patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 4, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 6, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

November 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

June 30, 2022

Status Verified

June 1, 2022

Enrollment Period

2 years

First QC Date

September 4, 2019

Last Update Submit

June 26, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • description of bone metastases detected by PET/CT in cancer patients.

    Analysis of number, type and SUVmax of metastatic bony lesions detected by PET/CT in cancer patients.

    one year

  • compare diagnostic performance of PET/CT, planar bone scintigraphy and SPECT/CT in detecting bone metastases

    compare sensitivity, specificity, PPV,NPV and accuracy

    one year

Secondary Outcomes (1)

  • risk benefit of PET/CT examination in cancer patients

    one year

Interventions

18F-fludeoxyglucose positron emission tomography/computed tomography

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will recruit patients diagnosed with different types of tumors with wide range of age, suspected or diagnosed to have bone metastases, and referred to nuclear medicine unit to perform PET/CT examination, or resulted in to have bone metastases.

You may qualify if:

  • patients diagnosed with different types of malignant tumor, suspected or diagnosed to have bone metastases and will do PET/CT examination
  • patients diagnosed with different types of malignant tumor, with accidently discovered bone metastases during PET/CT examination.
  • patients conscious to provide informed consent.

You may not qualify if:

  • pregnant women.
  • patients with blood sugar \> 200 mg/dL.
  • patients unable to sleep in a fixed position for 20 minutes.
  • severely ill patients who aren't capable of complying with study procedures or comatose patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university hospital

Asyut, Egypt

Location

Related Publications (6)

  • Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011 Apr;7(4):208-18. doi: 10.1038/nrendo.2010.227. Epub 2011 Jan 4.

    PMID: 21200394BACKGROUND
  • Choi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control. 2012 Apr;19(2):102-12. doi: 10.1177/107327481201900204.

    PMID: 22487972BACKGROUND
  • Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. doi: 10.1093/annonc/mdu103. Epub 2014 Apr 29.

    PMID: 24782453BACKGROUND
  • Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.

    PMID: 24411213BACKGROUND
  • Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer. 1997 Oct 15;80(8 Suppl):1595-607. doi: 10.1002/(sici)1097-0142(19971015)80:8+3.3.co;2-z.

    PMID: 9362427BACKGROUND
  • National Comprehensive Cancer Network (NCCN) Breast Cancer NCCN Practice Guidelines in Oncology. Fort Washington, PA:NCCN. 2014. Ver. 2.

    BACKGROUND

Study Officials

  • Mohamed A. Mekkawy, Prof. Dr

    Assiut University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

September 4, 2019

First Posted

September 6, 2019

Study Start

November 1, 2019

Primary Completion

November 1, 2021

Study Completion

December 1, 2021

Last Updated

June 30, 2022

Record last verified: 2022-06

Locations